Researchers working on the Human Functional Genomics Project have begun to unravel genetic relationships and variations in human immune response.
The company's approach investigates the utility of high-density lipoproteins as molecular markers for multiple diseases, starting with cardiovascular.
The Human Immunome Program, which is part of the Human Vaccines Project, eventually plans to profile B-cell and T-cell receptors in more than 1,000 individuals.
The new study in NEJM describes six families that share a disorder caused by mutations in IKAROS, a protein that plays a role in immune cell development.
The partners will identify novel drug targets in cancer, aging, and immune disorders, for which PhoreMost will develop small-molecule therapeutics.
After scrapping initial plans to develop a diagnostic instrument, the company has been working for several years to advance its single-cell droplet platform for targeted drug development.
Researchers have discovered links between disease-associated SNPs for four autoimmune disorders to genes and promoters far away.
Under the arrangement, OMRF will work with Biogen to analyze patient samples and identify biomarkers that indicate responses to particular therapies.
Four bacterial genera are found at lower levels in the gut microbiomes of three-month-old infants believed to be at risk of developing asthma later in life.
The companies anticipate launching the next-generation sequencing-based tests in Russia "in the near future."
In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.
The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.
Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.
In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.